John Anderson, MD
Allergy & Immunology · Homewood, ALNPI 1154543452
Payments from drug & device makers
Across 2,633 payments — averaging $1270.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1M
- Novartis$455K
- Biocryst Pharmaceuticals, Inc.$355K
- Takeda Pharmaceuticals U.S.A., Inc.$288K
- Shire North American Group Inc$239K
- Dermavant Sciences, Inc.$148K
- plus $850K from 42 others
Across 2 payments — averaging $245.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$491
What the payments were for
- Consulting fees$209,92027%
- Speaking & faculty fees$514,10565%
- Travel & lodging$31,3924%
- Food & beverage$33,7634%
- Education$2040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,346,324 in reported general payments places this provider in the 95th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 89 | $4,408,229 |
| IcatibantIcatibant Acetate | 75 | $1,347,066 |
| RuconestC1 Esterase Inhibitor, Recomb | 14 | $805,105 |
| HaegardaC1 Esterase Inhibitor | 24 | $551,973 |
| SajazirIcatibant Acetate | 15 | $388,615 |
| Dupixent PenDupilumab | 84 | $306,528 |
| XolairOmalizumab | 103 | $285,611 |
| NucalaMepolizumab | 36 | $125,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $89,925 |
| Dupixent SyringeDupilumab | 23 | $83,439 |
| FasenraBenralizumab | 12 | $63,189 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 33 | $51,104 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $30,650 |
| Spiriva RespimatTiotropium Bromide | 46 | $27,028 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $23,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $288,481 | $4,408,22989 claims |
| Pharming Healthcare, Inc.Ruconest | $141,246 | $805,10514 claims |
| CSL BehringHaegarda | $1,010,849 | $551,97324 claims |
| Cycle Pharmaceuticals IncSajazir, Cromolyn Sodium | $1,980 | $392,05234 claims |
| Genentech, Inc.Xolair | $251 | $285,611103 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $102,105 | $258,173267 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $37,983 | $95,83575 claims |
| Grifols USA, LLCGamunex-C | $247 | $51,10433 claims |
| Boehringer IngelheimSpiriva Respimat | $4,094 | $27,02846 claims |
| MerckDulera, Asmanex | $68 | $21,04568 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $48 | $6,69720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Homewood
- Lawrence SindelMobile$1.3M
- Joseph ForesterCullman$719K
- Njeri MainaBirmingham$241K
- Thomas AtkinsonBirmingham$155K
- William DavidsonDaphne$98K
- Michael PolcariBirmingham$86K
- Thomas ScottBessemer$65K
- Miranda CurtissBirmingham$46K
- Karen BarkerDaphne$19K
- Robert GreerMobile$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.